Abstract: In the pharmaceutical formulation of at least one alkali-sensitive active substance with an effervescent system, the carbonate component is embedded in at least one edible, organic acid and is preferably covered by said acid or by another acid. The active substance is embedded in at least one of the following compounds: an edible, organic acid, a higher alcohol, a hydrocolloid or a relatively long-chain polyvinylpyrrolidone, preferably covered with at least one of the stated compounds. The contact zone between active substance and effervescent system should have a pH of not more than 4.5. Both effervescent system particles and active substance particles, which are embedded or optionally covered in this manner, may be applied to carrier crystals of the same or another acid. The mixture is preferably pressed to give tablets. The acid provided for the embedding or covering may contain 0.1 to 3 mg of ethylenediaminetetraacetic acid per tablet.

Abstract: An effervescent granulate consisting of a solid water-soluble acidic substance, potassium carbonate and/or potassium hydrogen carbonate and one or more water-insoluble substances that are capable of absorbing water, a pesticidal active ingredient concentrate that is in the form of effervescent tablets and contains the effervescent granulate, and the preparation of the effervescent granulate and of the pesticidal active ingredient concentrate are described.

Abstract: The disclosed invention includes a base coated acid formulation which is highly compressible. The disclosed invention also relates to formulations including both an effervescent couple and an acid sensitive active agent. Formulations having an acid neutralization capacity of under 5.0 are also described as are methods of making particulate base coated acid and dosage forms using same.

Abstract: A pharmaceutical composition for oral use having analgesic activity containing a mixture of arginine and (S)-Ibuprofen in a molar ratio between 1.1 and 1.9 is described.

Abstract: Dental products employing a ternary surfactant system of poloxamers, anionic polysaccharides, and nonionic cellulose ethers. This ternary surfactant system has greatly enhanced foaming power relative to poloxamers alone or to poloxamers plus anionic polysaccharides or to poloxamers plus nonionic cellulose ethers. The poloxamer-anionic polysaccharide-nonionic cellulose ether surfactant system has little or no taste, is nonirritating, and has excellent adhesion to tooth surfaces and oral mucosa. Inclusion of a mild abrasive plus one or more of xylitol, raw licorice, licorice extract, and glycyrrhizin and its derivatives enhances the clinical efficacy of the formulations by further reducing plaque buildup thus brightening teeth and reducing tooth decay and periodontal disease.The surfactant system can be used in a dentifrice paste or gel, powder, granules, disintegrable tablet, and a mouthwash, lozenge, and chewing gum.

Abstract: The present invention relates to a novel pharmaceutical composition for the preparation of effervescent powders or tablets incorporating ibuprofen or one of its pharmaceutically acceptable salts as the active ingredient.This composition comprises:an effective amount of ibuprofen or one of its pharmaceutically acceptable salts;a pharmaceutically acceptable effervescent system comprising at least one alkaline carbonate and at least one organic acid, preferably in a sufficient amount to give a pH below about 8; andat least one pharmaceutically acceptable antioxidant in a sufficient amount to stabilize the ibuprofen.This composition has a remarkable stability both in powder form and in tablet form.

Abstract: The invention relates to effervescent pharmaceutical compositions for oral use comprising an effervescent couple consisting essentially of a base component and an acid component, which components react in the presence of water to generate a gas, and a compound which acts as a 5HT.sub.1 -like receptor agonist or a physiologically acceptable salt or solvate thereof as active ingredient.Methods for the manufacture of such compositions and for their use in the treatment of cephalic pain are also described.

Abstract: Free-flowing granular compositions principally for use in treatment of gastric disorders comprise (A) titanium dioxide having a particle size within the range from 10 nanometers to 60 nanometers and a specific BET (nitrogen) surface area of at least 30 m.sup.2 /g in combination with (B) an organopolysiloxane antifoam agent (for example a mixture of from 90 to 99 percent by weight of a polydiorganosiloxane and from 1 to 10 percent by weight of a finely-divided silica having a surface area to weight ratio of at least 50 m.sup.2 /g), (B) being present in a proportion of from 30 to 70 percent by weight calculated on the combined weight of (A) and (B). The compositions may contain from 40 to 60 percent of (B) based on the combined weight of (A) and (B). They may also contain an antacid or other medicament, glycerol, an effervescent agent and/or a disintegrant component.

Abstract: An effervescent ibuprofen preparation comprisinga) basic granules consisting of 1 part by weight of water-soluble ibuprofen salt, 2 to 10 parts by weight of excipient, 0.3 to 0.8 part by weight of stabilizer and 0.1 to 1 part by weight of sodium carbonate or potassium carbonate andb) 1 to 4 parts by weight of an acid component.

Abstract: The present invention is directed towards a process for producing a superior tasting pharmaceutical composition having porous granules produced through in situ gas generation using effervescence-producing ingredients. The method disclosed herein is especially suitable for producing superior tasting antacid tablets as well as superior tasting calcium supplements.

Abstract: A novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredients. The acetylsalicylic acid is in the form of a water soluble salt or complex and is in association with metoclopramide or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable hydrophilic polymer in an amount sufficient to stabilize the metoclopramide. This composition has remarkable stability in powder form and can be used to prepare sachets for the treatment of migraine.

Abstract: This invention provides a magnesium-added potassium-supplementing pharmaceutical composition containing 3 to 15 wt. %, as K, of a potassium-containing compound and 0.2 to 5 wt. %, as Mg, of a magnesium-containing compound in a K/Mg weight ratio of 20:1 through 1:1, and particularly a magnesium-added potassium-supplementing pharmaceutical composition in an effervescent dosage form which contains the above-mentioned ingredients, in the indicated ratio, in combination with 7 to 20 percent by weight of a blowing agent and 15 to 60 percent by weight of a neutralizing agent.

Abstract: The effervescent tablet contains an effervescent system composed of carrier crystals of at least one solid, edible, organic acid, at least one component which forms gas by reacting with the acid with salt formation and at least one salt formed from the acid and the gas-forming component. A first layer of a different acid and a second layer of a (preferably acidic) salt of at least one of the two acids are applied to the carrier crystals. Of the total amount of the acid(s) used and of the gas-forming components, 10 to 40, in particular 10 to 20, percent by weight are in the form of the salts, preferably in the form of acidic salts. Carrier crystals are, in particular, citric acid, malic acid, tartartic acid, monosodium citrate and/or ascorbic acid. The first layer may contain gluconic acid delta-lactone and is preferably covered with citric acid, malic acid and/or tartaric acid.

Abstract: A tableting aid including magnesium carbonate and an oil adsorbed thereon provides useful lubricating and disintegration properties. A free-flowing particulate flavoring additive including magnesium carbonate and a flavor oil adsorbed thereon, is also described.

Abstract: An aqueous solution or dispersion for oral intake of at least two different pharmaceutical active substances is prepared by dissolving or suspending at least two different effervescent, soluble and/or disintegrating mixtures in tablet or granule form, each of which contains a different active substance or a different active substance combination, in one and the same quantity of water. At least one of the tablets may be used only as a fragment, and at least one of the mixtures may weigh less than 2000 mg, preferably less than 1500 mg, in particular less than 1000 mg. In particular at least one of the mixtures contains diuretic, in particular hydrochlorothiazide and/or furosemide, and at least one of the further mixtures contains a beta-blocker and/or a vasodilator, in particular naftidrofuryl, calcium antagonist, ACE inhibitor or alpha-1-blocker. Such effervescent, soluble and/or disintegrating mixtures in tablet or granule form are preferably used for the treatment of hypertension.

Abstract: In an effervescent formulation containing morphine, inclusion of the morphine in the basic component gives superior storage stability.

Abstract: A drug delivery system includes a first capsule half having an inner chamber for containing a drug therein. A plug is disposed in a passageway of the capsule half for plugging the opening thereof. The plug is releasable from the passageway opening upon the application of pressure from within the inner chamber. A pump mechanism causes an increase in pressure within the inner chamber and forces the plug out of the passageway to release the drug from the inner chamber and out of the passageway thereby providing a second pulse of drug release at a predetermined time after initial ingestion of the capsule. The invention further provides a method of manufacturing the drug delivery system and method by which the drug delivery system provides the drug to the body.

Abstract: A readily dissolved carrier material having sufficient rigidity for administration of drugs, nutrients, vitamins, biologically-active materials, foodstuffs and combinations thereof capable of rapid dissolution by saliva, bodily fluids or other liquid comprising an interim skeletal structure of an ammoniated gel or foam forming material, preferably a proteinaceous material, such as gelatin, that has been ammoniated, rigidified such as with maltodextrin, in the ammoniated state and deammoniated to leave spaces in place of the frozen ammonia. On dissolution by saliva, bodily fluids or other liquids, the composition becomes a liquid system. While the oral route is preferred, other routes may be used to administer the compositions of this method.

Abstract: The present invention relates to an aqueous pharmaceutical suspension composition comprising: from about 0.2% to 20% of a substantially water insoluble pharmaceutical active, e.g. ibuprofen; a suspension stabilizing effective amount of xanthan gum, pregelatinized starch and polyoxyethylene sorbitan monooleate; an effective amount of taste masking composition; and water, as well as a process for producing such aqueous pharmaceutical suspensions.

Abstract: Bath compositions comprising a complex powder comprising a water-soluble polymer and a water-soluble aluminum salt; and also a bath composition which comprises a complex powder containing a water-soluble polymer, a polyphosphoric acid or a salt thereof and a water-soluble aluminum salt. Such compositions provide a refreshing and comfortable sensation of dryness to the skin; do not form water-insoluble particles, agglomerates, or flocculants; and provide an agreeable appearance and a pleasant feeling to the bath water.

Abstract: A granulate containing mesna is made by granulating mesna in the presence of an alcohol, acetone or a mixture of one of these with water. The granulate may be converted to tablets, along with other agents. The tablets contain:0.01-1 parts by weight of a binding agent0.03-0.4 parts by weight of a disintegrant0.01-0.2 parts by weight of a lubricant and0.1-1 parts by weight of a filling agent as well as, in the case of an effervescent tablet, an additional 0.05-30 parts by weight of a conventional physiologically acceptable effervescent mixture.

Abstract: The invention discloses an aqueous granulating solution containing sodium, potassium or mixed sodium potassium salt of an edible organic acid selected from the group consisting of citric, malic, tartaric and fumaric acid and optionally containing sodium or potassium bicarbonate. The granulating solution is especially useful for granulating finely divided solids including acetaminophen, ketoprofen or calcium carbonate. The resulting granulate may be used to prepare a swallow tablet or mixed with an edible organic acid and the mixture tableted to provide an effervescent tablet without resorting to controlled reaction or special handling techniques.

Abstract: A solid effervescent antacid formulation comprising as primary ingredients from about 35 to about 53 percent by weight of calcium carbonate, from about 0 to about 14 percent by weight of magnesium carbonate, from about 3.5 to about 7 percent by weight of a bicarbonate salt, from about 3.5 to about 7 percent by weight of malic acid and from about 21 to about 35 percent by weight of a bulking agent.

Abstract: The lozenge or chewable tablet contains, as the base, at least 30, preferably 50 to 70, percent by weight of an alkali metal and/or alkaline earth metal salt of at least one edible, organic acid, at least 10, preferably 20 to 40, percent by weight of a mixture of at least one unreacted, edible organic acid with at least one unreacted alkali metal or alkaline earth metal carbonate and/or bicarbonate and, if required, a pharmaceutical active substance and/or other conventional tablet assistants, such as flavors and sweeteners, disintegrants, hydrocolloids, etc.

Abstract: The invention provides a solid pharmaceutical composition for addition to water to produce a suspension of a drug comprising (a) a drug which is substantially water-insoluble or microencapsulated; (b) a thickening or suspending agent; (c) a pharmaceutically acceptable acid; (d) a pharmaceutically acceptable carbonate or bicarbonate; characterised in that the weight ratio of c+d:b is from 1:1.5 to 1:15 and the amount of c+d is sufficient to obtain rapid hydration of the thickening or suspending agent (b) when the composition is mixed with water such that a homogeneous suspension of the drug is obtained within 30 seconds. A method for preparing the composition is also described.

Abstract: The present invention is directed towards a process for producing a superior tasting pharmaceutical composition having porous granules produced through in situ gas generation using effervescence-producing ingredients. The method disclosed herein is especially suitable for producing superior tasting antacid tablets as well as superior tasting calcium supplements.

Abstract: A prolonged-release unit dosage formulation or pharmaceutical composition, preferably in tablet form, is described. The composition consists essentially of a gel-forming dietary fiber, a biologically-absorbable drug or other active therapeutic agent, and a disintegrant, namely, a mineral salt which releases a physiologically-acceptable gas upon ingestion, preferably carbon dioxide, e g., a mineral carbonate or bicarbonate, and advantageously dextrose or like soluble sugar. A physiologically-acceptable acid may optionally be included in the composition to further facilitate disintegration. The dietary fiber-containing composition, when compressed into a tablet together with the drug and the specific disintegrants, provides a unique and efficient prolonged-action drug-delivery system.

Abstract: A method for the treatment of gastrointestinal disorders associated with Helicobacter pylori infections which comprises administering to a patient an orally effective amount of triclosan is disclosed. The triclosan may be administered in the form of powders, granules, spheroids or liquids, or in unit dosage form as capsules or tablets containing 1 to 100 mg, preferably 10 to 60 mg, of triclosan. The triclosan may also be administered in gastric sustained release medicaments either as raft forming tablets or liquids, optionally to be co-administered with a solid pharmaceutically acceptable carboxylic acid or acid salt, or as mucoadherent-coated granules or spheroids.

Abstract: Granules, possibly pressed into the form of tablets, contain at least one insoluble, complexed or slightly soluble active substance in powder form which can bind or neutralize acids and which does not react with the acid of the effervescent system, and an effervescent system consisting of at least one organic, edible acid and at least one alkali metal and/or alkaline earth metal carbonate and/or bicarbonate. The active substance is present in an amount of 5 to 50, preferably 8 to 30, in particular 12 to 25%, by weight. It has an acid binding power of 2 to 40, preferably 3.5 to 25, meq/g, does not react with the acid of the effervescent system and increases the pH in 0.1N HCl during 2 min by a maximum of 0.5. It consists in particular of magnesium trisilicate, sucralfate and/or a bismuth salt. Each granule contains at least one acid component, at least one carbonate component and at least one active substance bound to one another.

Abstract: A composition excellent in dispersibility and diffusion in water, and storage stability comprising a) a pesticidal active ingredient, b) a surface active agent, c) a carbonate, d) a solid acid and e) at least one selected from the group consisting of boron oxide and metaboric acid, wherein at least one of the carbonate and the solid acid is water-soluble, the total content of the carbonate and the solid acid is in a proportion of 5-90% to the total weight, the weight ratio of the carbonate to the solid acid is in the range of 1:10-10:1, and the weight of at least one selected from the group consisting of boron oxide and metaboric acid is in a proportion of 0.5-40% to the total weight.

Abstract: A chewable tablet comprises a medicament dispersed in a chewable base, such as mannitol, together with an effervescent couple, such as citric acid - sodium bicarbonate. The combination of effervescence and chewability with optional flavorings improves the taste characteristics of the medicament in oral adminstration. A disintegrant such as microcrystalline cellulose may be added to give the patient the option of dispersing the tablet in water.

Abstract: The present invention relates to oral effervescent dosage forms for the administrations of an intended ingredient to children, and processes for their administration.

Abstract: Surface-treated sodium bicarbonate particles, the surfaces of which are coated with sodium carbonate or its double salt, are disclosed. Heat treatment or irradiation with micro waves o infrared light converts the surfaces of sodium bicarbonate particles into sodium carbonate. The surface-treated sodium bicarbonate particles exhibit an increased capacity to bind with other sodium bicarbonate particles as well as with other components when they are molded. They can be used as an excellent binder for molding various preparations. The products produced have a prolonged storage stability.

Abstract: The invention relates to a solid, rapidly disintegrating dosage form in the form of effervescent tablets for producing an aqueous suspension of diclofenac for peroral administration. The dosage form contains diclofenac in micronised form provided with a permeable, swellable coating, together with pharmaceutical excipients.

Abstract: A method of making a dosage device comprises admixing at least one active ingredient which is in solid form at 25.degree. C. and which has an average particle size of less than 5 microns, with a disintegrating agent, to provide a compressible mix; and compressing the mix into a unitary dosage device.

Abstract: The invention provides a pharmaceutical granule comprising cimetidine and 2-20% (w/w) relative to the cimetidine of a co-polymer of dimethylaminoethylmethacrylate and neutral methacrylic acid esters. Compositions of this invention have good palatability and dissolution characteristics.

Abstract: The invention provides a sustained release formulation of ketoprofen comprising granules each of which comprises a core comprising ketoprofen and microcrystalline cellulose and a coating comprising a water-soluble and a water-insoluble cellulose derivative.

Abstract: Anti-inflammatory pharmaceutical compositions with an ibuprofen base which eliminate the bitter taste, the burning in the throat and the topical toxicity at the level of the intestinal wall when their effervescent aqueous solutions are taken. The proportions among the main ingredients of each dose are the following: ibuprofen, 200 to 800 mg or ibuprofen sodium salt, 221.3 to 885.2 mg; sodium bicarbonate, 2.100 to 8.402 g; and citric acid, 0.450 to 1.800 g.

Abstract: A tablet formulation comprising: (i) a pesticide characterized by low or no water solubility, and (ii) a complementary delivery system containing an organic acid, an inorganic base, a dispersant, a disintegrant, and a wetting agent.

Abstract: A pharmaceutical dosage form incorporates microparticles which are susceptible to rupture upon chewing or which are adapted to provide substantially immediate release of the pharmaceutical ingredient contained in the microparticles. These microparticles are provided in a tablet with an effervescent disintegration agent. When the tablet is taken orally, the effervescent disintegration agent aids in rapid dissolution of the tablet and hence permits release of the microparticles, and swallowing of the microparticles, before the pharmaceutical ingredient is released from the microparticles. The system therefore provides particularly effective taste masking.

Abstract: A method for preventing the sickling of sickle cells in a patient having sickle cell disease, the method which comprises administering to the patient a therapeutically effective amount of a compound having the formula: ##STR1## wherein X.sup.- is selected from the group consisting of iodide, chloride, bromide, hydroxyl, nitrite, phosphate and acetate.

Abstract: It is known to produce effervescent tablets incorporating salicyl acid analgetics gained synthetically, and, is required, vitamin adjuvants. In order to avoid the disadvantages of synthetically manufactured salicyl acid in such effervescent tablets, namely the irritation of the gastric mucosas and the inhibition of thrombocyte aggregation, and simultaneously to bring about new fields of use for effervescent tablets, an effervescent tablet is suggested which has, as an analgesic agent forming salicyclic acid, a water-soluble plant extract of the salicis extract type (willow bark extract) with a high active substance content. Thus, a galenically appropriate administration form of these generally extremely hygroscopic extracts is obtained. In the effervescent tablet, high active substance quantities can be resorbed rapidly, the salicyl acid forming the final active substance only being formed in the liver.

Abstract: The invention relates to an effervescent product for the preparation of an oral rehydration solution for the treatment of diarrhoea. The product comprises oligosaccharides and/or disaccharides, and/or monosaccarides and/or amino acids as energy carriers, and (bi)carbonate and a bicarbonate precursor as alkalizing substances.The product has the form of a tablet or a powder.

Abstract: The reaction rate between aspirin and an equimolar amount of alkaline compound in an aqueous medium is increased by the inclusion of a surface-active agent such as lecithin or an oxyethylene-oxypropylene polymer. As a result the aspirin is completely dissolved within the aqueous medium to increase its availability in the body and reduce damage to gastro-intestinal mucosa, the primary adverse side effect of aspirin.

Abstract: A material and process for providing a corrosion inhibitor cationic film on he exterior aluminum surface of a weapon when contained in a submarine launch tube. An effervescent tablet containing a corrosion inhibitor material is disposed within the launch tube with the weapon and, upon flooding of the launch tube with seawater, the effervescent tablet releases the corrosion inhibitor material into the water to form a solution that coats the exposed aluminum surfaces of the weapon with a cation film of the corrosion inhibitor material.

Abstract: A bath preparation comprises a composition which, when dissolved in water, generates carbon dioxide, the composition being physically bound together as a tablet, with a colloidal material. The effervescence produced by dissolving the tablet improves dispersion of the colloidal material, and maintaining said colloidal material in dispersed form in the water for a longer period of time. The colloidal material is selected so as to provide relief from skin irritation. An acid, carbonate salt, and a colloidal material such as colloidal oatmeal may be tableted to provide an effective, easily stored and handled product.

Abstract: What is provided herein are substantially anhydrous complexes of PVP and H.sub.2 O.sub.2 in molar ratios of between about 2:1 and 1:1, respectively, which corresponds to between about 13% and about 23% by weight H.sub.2 O.sub.2. The complexes of the invention are prepared by an anhydrous process whereby substantially uniform, free-flowing, fine white powders are obtained.

Abstract: A method for preventing the sickling of sickle cells in a patient having sickle cell disease, the method which comprises administering to the patient a therapeutically effective amount of a compound having the formula: ##STR1## wherein X.sup.- is selected from the group consisting of iodide, chloride, bromide, hydroxyl, nitrite, phosphate and acetate.

Abstract: An effervescent pharmaceutical composition for oral use comprising ranitidine or a physiologically acceptable salt thereof, a monoalkali metal citrate, and an alkaline carbonate or bicarbonate.

Abstract: Preparation of an effervescent aqueous solution which has an emollient action on the cuticles of the nails, by dissolving the following anhydrous solid compounds substantially simultaneously in water: urea, pyrrolidonecarboxylic acid and an alkali metal and/or ammonium bicarbonate, and additional ingredients, the different compounds being introduced in the form of a mixture or of several separate mixtures prepared in advance. These mixtures are in pulverulent or tablet form.Composition for the preparation of the effervescent aqueous solution.Cosmetic treatment of the cuticle of the nails using the effervescent aqueous solution.